Cox-2 inhibitor

(redirected from Cyclooxygenase-2 inhibitor)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
  • noun

Words related to Cox-2 inhibitor

an anti-inflammatory drug that fights pain and blocks Cox-2 activity without impeding the activity of Cox-1

References in periodicals archive ?
The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.
Physicians should avoid nonselective NSAIDs and cyclooxygenase-2 inhibitors in patients with liver disease.
The FDA cited concerns with cardiovascular safety when it issued a "not approvable" letter for Merck's cyclooxygenase-2 inhibitor etoricoxib (Arcoxia) for the same indication in April.
The meeting panelists also voted 16-9 that there were not enough data to suggest that naproxen presented a substantially lower risk of CV events than did either ibuprofen or selective NSAIDs, such as cyclooxygenase-2 inhibitors.
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
Classes of drugs examined include SERMs and SERDs, aromatase inhibitors, microtubule binding agents, HER family inhibitors, angiogenesis inhibitors, miotic inhibitors, vaccines and immunomodulators, cyclooxygenase-2 inhibitors, and inhibitors of heat-shock proteins 90 and 27.
Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
The use of selective cyclooxygenase-2 inhibitors (coxibs) [5] and traditional nonsteroidal antiinflammatory drugs (tNSAIDs) has been documented to increase the incidence of myocardial infarction and stroke (1-3).
Potentiation of motexafin gadolinium cytotoxicity by celecoxib but not other cyclooxygenase-2 inhibitors.
Objectives: Although cyclooxygenase-2 inhibitors (coxibs) were developed to cause less gastrointestinal hemorrhage than nonselective nonsterodial antiinflammatory drugs (NSAIDs), there has been concern about their cardiovascular safety.
178 - Revision On Matrix MetalloProteinases 186 - Potential Window For Cyclooxygenase-2 inhibitors 190 - Apoptotis 194 - Overview of Apoptosis Therapies in Clinical Trial 201 - Therapeutic Importance of TRAIL-Receptor 205 - Approaches To Bypass the Bcl-2 Pathway 211 - Inhibitors of Apoptosis Proteins 216 - Caspase Inhibitors 221 - Multipathway Regulators 225 - Targeting Cell Cycle Control Elements 229 - Antisense Yet An Unproven Technology.
In 2001, a meta-analysis of Vioxx (ro-fecoxib) came out showing a substantial increase in heart attack, unstable angina, sudden cardiac death, and stroke with cyclooxygenase-2 inhibitors.
Other topics include Vitamin D use among adults in the United States, the use of selective Cyclooxygenase-2 inhibitors in breast cancer treatment and alternative approaches to cervical cancer prevention.
In 2001, a meta-analysis of Vioxx (rofecoxib) came out showing a substantial increase in heart attack, unstable angina, sudden cardiac death, and stroke with cyclooxygenase-2 inhibitors.
Full browser ?